Pain Management in Primary Care

Part Two

Joshua D. Dion MSN, APRN-BC, ACNP

Prescribers of Opioids

- Know how to start, modify, and discontinue opioids.
- Know how to convert from SA to LA or change from on SA to another SA or a LA to another LA.
- Understand that equal analgesic tables are a guide and are not 100% correct. Take into account incomplete cross-tolerance.

Commonly Used SA Opioids

Drug	Dosing Strengths mg	Dosing Frequency	Maximum Daily Dose
Oxycodone Oxycodone/ Acetaminophen Aspirin Ibuprofen	5,10,15,20,30 2 .5,5,7.5,10 325 to 650 4.8/ 325 5/400	5 to 30 mg q4 prn 2.5 to 10 mg q4 to 6 prn q6 prn qd to qid prn	Not defined 4 grams Acet. In 24 hr. 12 per 24 hr. 4 per 24 hr.
Hydrocodone/ Acetaminophen Ibuprofen	2.5,5,7.5,10 300 to 700 mg 200	2.5 to 10 mg q4 to 6 prn q4 to 6 h prn	4 grams Acet. in 24 hr. Max 5 qd
Hydromorphone	2,4,8	2-8 mg q3 to 4 prn	Not defined
Morphine IR	15,30	10-30 mg q3 to 4 prn	Not defined
Nucynta	50,75,100	50 to 100 mg q4 to 6 prn	Not defined

Long-Acting Opioids Currently Available

Drug	Dosing Interval	Available Strengths	Administration	Bolus	Ceiling dose
KADIAN®	q12hr q24hr	20, 30, 50, 60, 100 mg	Capsule, Sprinkle, G-Tube	No	ı
AVINZA®	q24hr	30, 60, 90, 120 mg	Capsule, Sprinkle	Yes	1600 mg/day
OxyContin®	q12hr	10, 20, 40, 80, 160 mg	Tablet	Yes	-
MS Contin®	q8hr q12hr	15, 30, 60, 100, 200 mg	Tablet	No	-
Duragesic®	q48 hr q72hr	12, 25, 50, 75, 100 mcg/hr	Transdermal Patch	No	-

Long-Acting Opioids (continued)

Opana ER _®	Q 12hr	5, 10, 20, 40	Tablet	No	-
Exalgo ®	Q 24 hr	8,12,16 mg	Tablet	No	1
Butrans®	Q week	5, 10, 20 mcg/hr	Transdermal Patch	No	ı
Nucynta ER®	Q 12 hr	50,100,150, 200, 250	Tablet	No	-

Products to avoid (or use cautiously)

- DO NOT USE PLACEBOS
- Avoid
 - Demerol
- Use Cautiously
 - Codeine
 - Tramadol
 - Agonist/antagonist drugs
 - Methadone

Risk Evaluation and Mitigation Strategies.

- FDA amendments act of 2007 allowed the FDA to initiate requirements to minimize the risks of certain medications.
- REMS can be mandated for any medication class and certain opioids have been included.
- Participation in REMS is currently Voluntary
- REMS Online CME Course available through Boston University: WWW.SCOPEOFPAIN.COM

Risk Evaluation and Mitigation Strategy (REMS)

Pros

Address the potential problems associated with prescribing opioids (physicians, NP's, and PA's).

- Education on proper patient selection and tools for patient education.
- Paid for by Pharmaceutical manufacturers.

Cons


- Could limit access for patients.
- Time requirements for providers to train on each drug are not known.
- Limited to Long acting opioids only.

Polypharmacy

- For predictable/steady pain
 - Provide estimated need in LA meds
 - Have 10-25% of daily dose for breakthrough pain episodes
- One drug per class (exc. LA / SR MS)
- Different metabolism / excretion
- Different toxicity / Side effect profile
- Better than irrational polypharmacia



•	
•	
•	
•	
•	
,	



Questions on	Pharmaco	logy?
--------------	----------	-------

Screening of Pain Management Referrals

- Require referral from current treating provider, regardless of insurance plan.
- Require 3 to 6 months of office notes and all pertinent diagnostics pertaining to the condition.
- Require all notes from specialists and/or previous pain care providers.
- Use caution accepting self pay patients.

Risk Assessment for Opioid Use

- Pros
- -Protects the patient, the public, and your practice.
- -Helps determine most appropriate treatment protocol.
- -Compliance monitoring (frequency of pill counts and UDS)
- Cons
- -Difficult to find a provider to screen patients.
- -Assessments can be open to interpretation.
- -Cost can be prohibitive for patients if not covered on insurance plan.
- -How to chose which patients need to be screened.

In Office Assessment of Addiction

- Tools available:
- ORT (Opioid Risk Tool) http://www.partnersagainstpain.com/printouts/ Opioid_Risk_Tool.pdf
- SOAPP (Screener and Opioid Assessment for Patients in Pain) http://www.painedu.org/soap.asp
- COMM (Current Opioid Misuse Measure) http://www.painedu.org/soap.asp

High Risk: Likelihood of Misusing Opioid Medications.

- May chose to use only non-opioid medications and alternate treatment modalities.
- If prescribing of opioids is initiated, use longer acting products, smaller quantities, frequent visits, more frequent UDS, and random pill counts.
- Re-screen if any signs of aberrant behaviors.
- Consider NA and/or AA services if needed.
- Role of Methadone /Suboxone Clinics for detoxification.

•	

Low Risk: Unlikely to misuse opioid medications.

- Set clear expectations for treatment with opioids and sign treatment agreement.
- UDS on day of first RX to ensure compliance with current and/or reported medication regimen and to ensure no other illicit or prescribed drugs are present.
- Perform random UDS and pill counts.

Pain Treatment Agreements

Positives

- -Clear expectations
- -Informed Consent
- -Documentation
- -Patient safety
- -Safe Guarding **Practice**

Negatives

- -Patient Perceptions about agreements
- -Open to interpretation.
- -Time and staff power needed to keep agreements up to date.

PAIN TREATMENT AGREEMENT

I, understand that compliance with the following g is important in continuing pain treatment with Integrated Pain Care.

medications prescribed by my provider in the original solutes are provides a unit was prein larger to participate in psychiatric or psychological assessments, if necessary,
if larger to participate in psychiatric or psychological assessments are provided in the psychological assessments are provided in the psychological assessments are psychological assessments and psychological assessments are psychological assessments and psychological assessments are psychological assessments and psychological assessments are psychological assessments. If have psychological assessments are psychological assessments are psychological assessments are psychological assessments. I will not destroy or dispose of any discontinued or currently prescribed medications written by an integrated Pan Cale Provider unless specifically instructed to do as

		_	
	 I understand that in the event of an emergency, this provider should be contacted and the problem will be discussed with the emergency room or other treating provider. I am responsible for signing a consent to request record transfer to this provider. 		
	3.1 understand that I will consent to random drug screening. Urne orig teating to low foreign the low foreign to the low foreign to the low foreign to the low foreign to low foreign the low foreign to the low foreign to the low foreign to the low foreign to low foreign the low foreign		
	grounds for termination of the provider/patient relationship.		
	A. I will keep my scheduled appointments and/or cancel my appointment a minimum of at least 24 hours prior to the appointment.		
	E. I understand that this provider may stop prescribing opioids, change the treatment plan, or terminate the patient/provider relationship if: a. I do not show any improvement in pain from opioids or my physical activity has not a.		
	pilan, or terminate the patient/provider relationship from opinities or my physicial activity has not improved. Improved. 1. In provider in constance with the responsibilities sufficient in #1 above. 2. I give, set for relatives the opinities medications. 3. I give, set for relatives the opinities medications. 4. I evidency regist training or foliation from the provider of t		
	c. I give, sell or misuse the opioid medications. d. I develop rapid tolerance or loss of improvement from the treatment.		
	declaration opioids from someone other than this provider. I refuse to cooperate when asked to get a drug screen or a pill count. If an addition problem is transfer as a result of prescribed treatment or any other. If an addition problem is transfer as a result of prescribed treatment or any other. If an addition problem is transfer as a result of prescribed treatment or any other.		
	addictive substance. h. I am unable to keep follow-up appointments with Integrated Pain Care and other		
	facilities as outlined in my individual treatment plan. i. I test positive for any illicit substance, which includes but is not limited to cocaine, PCP.		
	j. If I stop my medication without instruction to do so from my provider and/or I fail to inform my provider of any side effects or adverse reactions to any of my medications.		
	YOUR SAFETY RISKS WHILE WORKING UNDER THE INFLUENCE OF OPIODS		
	You should be aware or potential side effects or opioids stuff as decleased, the clouded judgment, drowsliness and tolerance. Also, you should know about the possible degrees associated with the use of opioids while operating heavy equipment or driving.		
	YOUR SAFETY RISKS WHILE WORKING UNDER THE INFLUENCE OF OPIODS You should be wear owner to be an observable of the second of the		
	Confusion or other change in thinking abilities Problems with coordination or balance that may make it unsafe to operate		
	 Breathing too slowly – overdose can stop your breathing and lead to death 		
	Nausea Constipation Steepiness or drowsiness		
	Aggravation of depression Vomiting		
	Aggravation of depression Vomiting Dry Mouth These alide effocts may be made worse if you mix opioids with other drugs, including alcohol.	_	
		_	
-		7	
	RISKS:		
	 Physical dependence means that if the opioid medication is abruptly stopped or not taken as directed, a withdrawat symptom can occur. This is a normal physiological 		
	taken as dimoted, a withdrawal symptom can occur. This is a normal physiological response. The withdrawal syndrome could include, but are not limited to, exeeting, nervoueness, adodimate cramps, distribute, goose bumps, and attentions in norsh mood, dependent or in result in the state of th		
	It should be noted that physical dependence does not equal addiction. One can be dependent on insulin to treat diabetes or dependent on prednisone (steroids) to treat		
	asthma, but one is not addicted to the insulin or prednisone. 2. Tolerance means a state of adaptation in which exposure to the drug induces changes		
	that result in decreased effectiveness or one or more of the drug's effects over limits. The does of the optical may have to be adjusted up or down to a dose that produces maximum function		
	and a reassure accrease of the patient's pain. 3. Addiction is a primary, chronic neurobiologic disease with genetic, psychosocial and		
	by behavior that includes one or more of the following: impaired control over drug use,		
	decreases one's quality of life. 4. Problems with pregnancy, if you are pregnant or contemplating pregnancy, discuss this		
	with your provider I will inform my provider if I become pregnant while under their care.		
	I have road this document, understand and have had all my questions answerdu satisfactorily. I consent to the use of opioids to help control my pain and I understand that my treatment with opioids will be carried out as described above.		
	Patient Signature Date		
	Provider Signature Date		
	Witness Signature Date		
	PharmacyPhone		
	Pharmacy		
		_	
		7	
		I	
		I	
	The purpose of this agreement is for me,		
	The pain management program at Integrated Pain Care is designed to help me learn to cope with my pain. The goals include changing those actions and attitudes that are associated with the pain, and		
	learning to manage my life and work in ways that will be more productive and satisfying.		
	An overall goal is to gain control of my pain problem so that I can do more things that are considered normal for a person of my age. Specifically, I have the following goals:		
	1.	1	
	2.	I	
	4.	1	
	I recognize that members of my family and others significant to me are considered essential in	1	
	I recognize that members of my family and others significant to me are considered essential in helping me to break old habits and to learn new ways to live with the pain. As a result, I will actively encourage these individuals to participate in my program. I understand that you may, with my consent,	I	
	speak with members of my family if that will improve the chances of my attaining my goals. I understand	1	
	that I will be informed before other people are contacted.	I	
	activities. Pain is no excuse. I further understand that my absence for a total of three days will be grounds for dropping me from the program due to non-compliance.	I	
	I understand that my provider will outline a plan of care based on my own individual needs and I	1	
	am expected to attend all scheduled visits in my treatment plan. Including but not limited to:	I	
	Physical/Occupational Therapy Nutrition	I	
	Psychology Interventional Procedures	I	
	Acupuncture/Bowenwork Diagnostic Imaging	I	
	I further understand that my absence for a total of three scheduled sessions of any aspect of my	I	
	treatment plan with these independent providers will be grounds for dropping me from the program due to non-compliance.	1	
	the state of the s		

	1
I will immediately inform the staff about all other medical appointments outside the program. I will immediately inform the staff about any change in use of medication obtained outside this program.	
On the basis of my treatment needs, I and members of the treatment team will decide what the	
this program are paid for by my workers compensation insurer, conditional upon my continued all costs of the program are paid for by my workers compensation insurer, conditional upon my continued eligibility for workers compensation benefits. I understand and agree to the above conditions, and I acknowledge that the Pain Management Program has now been explained to my satisfaction.	
Topolis no to the control of the statements.	
Patient Signature Date	
Printed Namo	
Integrated Pain Care Provider Date	
	1
Committee Manitaria	
Compliance Monitoring	
Positives Negatives	
• Necessary to • Cost	
protect the patient, • Staffing	
provider, and Time	
society. • Monitors • Patient complaints	
adherence to	
treatment protocol	
	1
Laboratory Information	
Laboratory Information	
• Know the cut off levels for a given drug.	
Know which drugs are screened for on a	
standard panel and which need to be	
added.	
 If using a commercial lab, ensure that pricing information is available for a given 	
panel and add ons.	

• Have a go to person to address problems

or concerns.

Toxicology Report Examples

Random Result Negative Negative Negative Negative Negative Negative POSITIVE	Tost(s		500 200 75 5		Expanded (Urine
Result Negative Negative Negative Negative Negative Negative Negative	Test(s		500 200 75 5	Unit ng/mL ng/mL ng/mL	
Negative Negative Negative Negative Negative		C	500 200 75 5	ng/mL ng/mL ng/mL	Loc
Negative Negative Negative Negative Negative			200 75 5	ng/mL ng/mL	
Negative Negative Negative Negative			75 5	ng/mL	
Negative Negative Negative			5		
Negative Negative				ng/mL	
Negative					
			20	ng/mL	
POSITIVE				ug/mL	
				ng/mL	
POSITIVE	INCONSISTENT		30	ng/mL	
	32905	5		ng/mL	
Negative				ng/mL	
Negative				ng/mL	
Negative				ng/mL	
Negative	INCONSISTENT			ng/mL	
Negative				ng/mL	
Negative				ng/mL	
Negative				% (w/v)	
Normal			5		
				mg/aL	
	6.3				
			200	ug/mL	
Oxycontin					
	Negative Normal	Normal 25.3 6.3	Normal 25.3 6.3 Negative	Normal 5 25.3 6.3 Negative 200	Normal 5 mg/dL 25.3 mg/dL 6.3 Negative 200 ug/mL

Urine Drug Test - Quick Referernce

"Positive Consistent" drug for metabolite of decided and IS included in list of medications
"Positive Inconsistent" drug for metabolite objected and IS NOT included in list of medications
"Negative Inconsistent" drug for metabolite of NOT detected or below cutoff level and IS included in list of medications
Cocarine

Drug Reason for Positive Consistent / Inconsistent Detection Window

Benzoyleogonne Metabolite of Cocarine Metabolite of Chloridiazepoxide (Librium) 1-4 Days Detection Window 1-4 Days

Laboratory Accession:		Doi	nor's Name:		
Container(s): 01: Urine	Urine, Random	Test(s):	70195 Det	ectiMed Panel	Expanded (Urine)
Analyte Name	Result		Cut-off	Unit	Loc
AMPHETAMINES	Negative		500	ng/mL	
BARBITURATES	Negative		200	ng/mL	
BENZODIAZEPINES	Negative		75	ng/mL	
BUPRENORPHINE/METABOLITE	Negative		5	ng/mL	
CANNABINOIDS	Negative		20	ngimt	
CARISOPRODOL/METABOLITE	Negative		100	ng/mL	
COCAINE/METABOLITES	Negative		150	ng/mL	
FENTANYL	POSITIVE			ng/mL	
Fentanyl	POSITIVE	CONSISTENT	0.5	ng/mL	
Fentanyl, Quant		46.7		ng/mL	
Norfentanyl	POSITIVE	CONSISTENT	0.5	ng/mL	
Norfentanyl, Quant		≥100		ng/mL	
METHADONE/METABOLITE	Negative		100	ng/mL	
OPIATES	POSITIVE			ng/mL	
Hydromorphone	POSITIVE	CONSISTENT		ng/mL	
Hydromorphone, Quant		50		ng/mL	
PROPOXYPHENE/METABOLITE	Negative		300	ng/mL	
TRAMADOL/METABOLITE	Negative			ng/mL	
ALCOHOLS	Negative			96 (w/v)	
ACETAMINOPHEN	Negative			ug/mL	
CREATININE	Normal			mg/dL	
Creatinine, Quant		154.6		mg/dL	
nH	Normal	104.6		myrac	
GENERAL OXIDANTS	Negative		200	ug/mL	
MEDICATIONS LISTED:	Negative		200	og/mc	
1)	Dilaudid				

Laboratory Acce	ssion:	Donor's Name:	
	Urine Drug To	est - Quick Referernce	
"Positive Consis		tected and IS included in list of medication	ns
"Positive Incons	istent" drug (or metabolite) det	tected and IS NOT included in list of medi	
"Negative Incon	sistent" drug (or metabolite) NC	OT detected or below cutoff level and IS in Fentanyl	
Drug	Reason for Positive C	consistent / Inconsistent	Detection Window
Fentanyi	Use of Fentanyl (Actiq, Duragesic, Sublin	maze) morphine metabolism	2-6 Days
	No	orfentanyl	
Drug	Reason for Positive C	onsistent / Inconsistent	Detection Window
Norfentanyl	Metabolite of Fentanyl; Use of Fentanyl (metabolism	2-6 Days	
		Opiates	
Drug	Reason for Positive Co	onsistent / Inconsistent	Detection Window
Hydromorphone	Use of hydromorphone; Metabolite of Hydromorphine metabolism	1-4 Days	

Laboratory Accession:	Dor	Donor's Name:				
Container(s): 01: Urine	Urine, Random					
Analyte Name	Result	Test(s):			Expanded (Urine)	
AMPHETAMINES			Cut-off	Unit	Loc	
BARBITURATES	Negative Negative			ng/mL		
BENZODIAZEPINES	Negative			ng/mL		
BUPRENORPHINE/METABOLITE	Negative			ng/mL		
CANNABINOIDS	Negative			ng/mL		
CARISOPRODOL/METABOLITE	Negative			ng/mL		
COCAINE/METABOLITES	Negative			ng/mL		
FENTANYI	Negative			ng/mL		
METHADONE/METABOLITE	Negative			ng/mL		
DPIATES	POSITIVE					
Morphine	POSITIVE	CONSISTENT		ng/mL		
Morphine, Quant	POSITIVE	>10000	10	ng/mL		
Codeine	POSITIVE	INCONSISTENT	40	ng/mL ng/mL		
Codeine Quant	POSITIVE	INCONSISTENT 15	10	ng/mL ng/mL		
Hydromorphone	POSITIVE	CONSISTENT	40			
Hydromorphone, Quant	POSITIVE	5R2	10	ng/mL		
PROPOXYPHENE/METABOLITE		582		ng/mL		
RAMADOL/METABOLITE	Negative			ng/mL		
LCOHOLS	Negative			ng/mL		
CETAMINOPHEN	Negative			% (w/v)		
REATININE	Negative			ug/mL		
	Normal		5	mg/dL		
Creatinine, Quant		95.9		mg/dL		
H	Normal					
SENERAL OXIDANTS	Negative		200	ug/mL		
MEDICATIONS LISTED:	MC Contin					

		Urine Drug Test - Quick Referernce					
"Positive Consistent"		drug (or metabolite) detected and IS included in list of medications					
"Positive Inconsistent"		drug (or metabolite) detected and IS NOT included in list of medications					
"Negative Incon	ilstent"	drug (or metabolite) NOT detected or below cutoff level and IS inc Opiates	cluded in list of medication				
Drug		Reason for Positive Consistent / Inconsistent	Detection Window				
	Use of Codeir	ne and/or Codeine formulation; Low levels could result from dietary py seeds; Low levels could be due to an impurity in "street" heroin	1-4 Days				
Codeine	intake of pop	r, see of the day to diff imparity in sheet fielding					
Codeine	Use of Morphi	ine; Metabolite of Codeine; Low levels may result from dietary py seeds; Metabolite of Heroin, 6-MAM may also be detected	1-4 Days				
	Use of Morphi intake of pop	ine; Metabolite of Codeine; Low levels may result from dietary py seeds; Metabolite of Heroin, 6-MAM may also be detected norphone; Metabolite of Hydrocodone; Low levels consistent with	1-4 Days				

Laboratory Accession:		Dos	nor's Name:		
Container(s): 01: Urine	Urine, Random	Test(s):	70195 Det	ectiMed Panel,	Expanded (Urine)
Analyte Name	Result		Cut-off	Unit	Loc
AMPHETAMINES	POSITIVE		500	ng/mL	
Amphetamine	POSITIVE	INCONSISTENT	50	ng/mL	
Amphetamine, Quant		≥10000		ng/mL	
BARBITURATES	Negative		200	ng/mL	
BENZODIAZEPINES	POSITIVE		75	ng/mL	
Lorazepam	POSITIVE	INCONSISTENT	50	ng/mL	
Lorazepam, Quant		1320		ng/mL	
BUPRENORPHINE/METABOLITE	Negative		5	ng/mL	
CANNABINOIDS	Negative			ng/mL	
CARISOPRODOL/METABOLITE	Negative			ng/mL	
COCAINE/METABOLITES	Negative			ng/mL	
FENTANYL	Negative			ng/mL	
METHADONE/METABOLITE	Negative			ng/mL	
OPIATES	POSITIVE			ng/mL	
Morphine	POSITIVE	INCONSISTENT	10	ng/mL	
Morphine, Quant		>10000		ng/mL	
Hydromorphone	POSITIVE	INCONSISTENT	10	ng/mL	
Hydromorphone, Quant		162		ng/mL	
Oxycodone	POSITIVE	CONSISTENT	10	ng/mL	
Oxycodone, Quant Oxymorphone		11		ng/mL	
	POSITIVE	CONSISTENT	10	ng/mL	
Oxymorphone, Quant		29		ng/mL	
PROPOXYPHENE/METABOLITE	Negative			ng/mL	
TRAMADOL/METABOLITE	Negative			% (w/v)	
ACETAMINOPHEN	Negative			ng/mL	
CREATININE	Negative Normal			ug/mL	
Creatinine Quant	Normal	157.1	5	mg/dL	
oH		157.1		mg/dL	
SENERAL OXIDANTS	Negative	6.4	000		
MEDICATIONS LISTED:	Negative		200	ug/mL	
1)	Perconet				

		Urine Drug Test - Quick Reference	
"Positive Consis		drug (or metabolite) detected and IS included in list of medication	ans
"Positive Incons		drug (or metabolite) detected and IS NOT included in list of medi	fications
"Negative Incon	sistent"	drug (or metabolite) NOT detected or below cutoff level and IS in Amphetamine	cluded in list of medications
Drug		Reason for Positive Consistent / Inconsistent	Detection Window
Amphetamine	Use of Amp	phetamine (Adderall); Metabolite of Methamphetamine	1-4 Days
		Benzodiazepines	_
Drug		Reason for Positive Consistent / Inconsistent	Detection Window
Lorazepam	Use of Loraz	szepam (Ativan)	1-10 Days
		Opiates	
Drug		Reason for Positive Consistent / Inconsistent	Detection Window
Morphine	Use of Morp intake of pr	phine; Metabolite of Codeine; Low levels may result from dietary oppy seeds; Metabolite of Heroin, 6-MAM may also be detected	1-4 Days
Hydromorphone	Use of hydro morphine m	romorphone; Metabolite of Hydrocodone; Low levels consistent with netabolism	1-4 Days
Oxycodone	Use of oxyco	codone &/or oxycodone formulation morphine metabolism	1-4 Days
Oxymorphone	Use of oxym	norphone; Metabolite of Oxycodone morphine metabolism	1-4 Days

Ongoing Assessment for Opioid Management.

- 4 A's: Analgesia, ADLS, Adverse Events, Aberrant Behaviors.
- Frequency of visits
- Have a system in place to deal with noncompliance and/or issues with lost or stolen medications.
- Know of resources in your region that can deal with addiction, abuse, diversion

Multidisciplinary Pain Care

- Pros:
- Improved patient outcomes
- Multifaceted approach with less reliance on one modality.
- Decreased long term cost for insurers.
- Difficulties:
- Overhead Costs.
- Coordination of care incorporating multiple specialties.
- Patient compliance.
- Buy in from insurers.
- Support from referral sources.

Case Study Acute Back Pain

- 38 yo male construction worker injured his lower back picking up a 100 pound bag of concrete mix x 3 days ago.
- Reports feeling an initial burning sensation in his lower back that progressively became more problematic as his work day progressed and states it is now a constant ache.
- Denies a radicular component or any associated symptoms.

_					
_					
_					
-					

Case Study Acute (continued).

- Patient X has tried taking Tylenol and using ice compresses with minimal benefit.
- PE: 2 + lumbar paraspnial muscle tenderness and spasm noted bilaterally. No lumbar spinous process tenderness, no SI joint tenderness, negative straight leg raise while sitting and supine, ROM limited to pain in all plains of motion, stretngth is 5/5 BLEs with flexion and extension. Reflexes are 2+ patella and achilles bilaterally.

Case Study Acute (continued)

- Assessment: Lumbar strain
- Plan: OTC NSAIDs and course of PT with a focus on proper lifting techniques, postural exercises, and stretching, 40 pound weight restriction at work.
- Outcome: Patient completed PT in 4 weeks and is performing HEP at home. No longer on NSAID and is back to full duty without restrictions.

Case Study: Chronic Back Pain

- 45 yo male with a c/o back pain x 3 years s/p lifting injury at work. Reports lifting a heavy object in a forward flexed position when he felt a popping sensation in his lower back and pain down into his RLE.
- Initially Presented to occupational health and was referred for a course of PT, given a medrol dose pak, and flexeril for his pain, with poor response and has been on light duty since the injury.

Chronic Pain Case (continued)

- MRI of Lumbar spine revealed an L4-5 HNP with NF narrowing on the right.
- Patient did not want surgery or injections therefore was put on Percocet per PCP to manage his symptoms medically.
- Pain became more problematic and medications were becoming less effective.
 PCP referred for Pain Management Evaluation.

Chronic Pain Case (continued)

 PE: Pain to palpation along lumbar paraspinal musculature bilaterally, no lumbar spinous process tenderness or SI joint tenderness noted. ROM limited with forward flexion and lateral flexion to the right due to pain. SLR positive at 45 degrees on the right. Strength 4+/5 in RLE and 5/5 LLE. Reflexes wnl. Decreased sensation to light touch along the L5 dermatomal distribution in the RLE as compared to the LLE.

Chronic Pain Case (continued)

- Assessment:
- 1. Lumbar HNP at L4-5 with a radicular /neuropathic component to pain along L5 distribution.
- 2. Opioid dependence: using # 6 10/325 mg Percoet per day.
- 3. Alternate medications: May benefit from trial of Gabapentin for radicular pain.
- 4. Needs another course of PT for strengthening of RLE.

-				
_				
-				
-				
-				
-				
-				
-				
-				
_				
-				
-				
-				

Chronic Pain Case (continued)

Plan:

- 1. Obtain EMG of RLE to R/O a radiculopathy.
- 2. Change opioid regimen to Roxicodone 15 mg tid prn to eliminate long term Tylenol use, decrease frequency of dosing, and lower total daily dose of opioid.
- 3. Add Neurontin to medication regimen for neuropathic component.
- 4. Course of PT.
- 5. Consider interventional options if above fails

Chronic Pain Case (continued)

- Outcome: EMG showed a slight right sided L5 radiculopathy. Neurontin was titrated to 1800 mg/day and patient was able to decrease Roxicodone frequency to bid prn, taking at end of work day.
- Patient did well in PT and was able to increase his hours from 24 to 32 hours per week and his lifting capacity was increased from 10 to 25 pounds.
- Patient wishes to forego surgery or procedures at this time.

